FLT3 and acute myeloid leukemia: Casirati and colleagues [107] focused on AML and generated epitope-engineered HSCs with base edits for point mutations in FLT3 or CD135, the α-subunit of IL-2 receptor or CD123 [110], and KIT or CD117, including by multiplexing these edits.